Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy.

Autor:	Sugiura Y; Department of Pulmonary and Thoracic Surgery., Nemoto E; Department of Pulmonary and Thoracic Surgery., Kawai O; Department of Respiratory Medicine, Kanagawa National Hospital, Hadano, Japan., Ohkubo Y; Department of Respiratory Medicine, Kanagawa National Hospital, Hadano, Japan., Fusegawa H; Department of Respiratory Medicine, Kanagawa National Hospital, Hadano, Japan., Kaseda S; Department of Pulmonary and Thoracic Surgery.
Jazyk:	angličtina
Zdroj:	Lung Cancer (Auckland, N.Z.) [Lung Cancer (Auckl)] 2013 Jun 08; Vol. 4, pp. 9-14. Date of Electronic Publication: 2013 Jun 08 (Print Publication: 2013).
DOI:	10.2147/LCTT.S45172
Abstrakt:	Background: Gefitinib is known as one of the agents for treating patients with both advanced lung cancer and an epidermal growth-factor receptor mutation. In the epidermal growth-factor receptor-mutant advanced non-small-cell lung cancer population, gefitinib therapy has been associated with increased response rate, longer progression-free survival, and better quality of life compared to other anticancer drugs. However, gefitinib has to be discontinued for patients in whom adverse events occur, even if it is still effective. Here, we retrospectively assessed the clinical course of patients receiving gefitinib therapy, with a particular focus on liver damage. Patients and Methods: Of 24 Asian patients treated with 250 mg gefitinib daily at Kanagawa National Hospital, Japan, between January 2008 and June 2012, grade 3 liver damage (Common Terminology Criteria for Adverse Events, version 4.0) occurred in nine and were eligible for our assessment. The regimen was subsequently changed to alternate-day administration. The relationships between liver damage and each clinical factor were retrospectively examined using Fisher's exact test. Results: Of the nine patients with liver damage, seven had previous exposure to another anticancer drug. There was a significant relationship between the incidence of liver damage and previous chemotherapy ( P = 0.009). The objective response rates of patients treated with daily gefitinib 250 mg and alternate-day gefitinib following liver damage were 66.7% and 46.7%, respectively; these were not significantly different ( P = 0.597). Conclusion: Gefitinib for advanced adenocarcinoma patients who have previously undergone chemotherapy should be used cautiously and liver function monitored closely, because it frequently induces significant liver damage. The alternate-day administration of gefitinib may be a suitable option for patients in whom daily gefitinib therapy induces liver damage. Competing Interests: Disclosure The authors report no conflicts of interest in this work.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu